ALBPS.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	69 814.00
Średni wolumen	60 708.00
Kapitalizacja rynkowa	2.88M
EPS	€0 ( 2024-04-14 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.0700
ATR14	€0.00600 (0.73%)

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: -0.73 (moderate negative)

Signal:(48.294) Neutral

Biophytis SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biophytis SA Korelacja - Waluta/Towar

-0.37
( neutral )

0.64
( weak )

0.00
( neutral )

-0.43
( neutral )

-0.64
( weak negative )

-0.77
( moderate negative )

Biophytis SA Finanse

Annual	2023
Przychody:	€0
Zysk brutto:	€-803 000 (0.00 %)
EPS:	€-12.54

FY	2023
Przychody:	€0
Zysk brutto:	€-803 000 (0.00 %)
EPS:	€-12.54

FY	2022
Przychody:	€0
Zysk brutto:	€-484 000 (0.00 %)
EPS:	€-0.130

FY	2021
Przychody:	€0.00
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-0.260

Financial Reports:

No articles found.

Biophytis SA

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.